VolitionRx - רווח עתידי VNRX

סמל ולוגו של המותג volition.com (VNRX)

VolitionRx Limited (VNRX) is scaling sales of its unique reagents leveraged by patent protection. The core of the business is the Nu.Q epigenetic environment, which integrates liquid biopsy into partner laboratories, creating significant switching costs for customers. The trend in expected profitability confirms this resilience, where the 0.02 metric determines the parameter status. High capacity utilization of modernized test production facilities completes the overall growth picture.

VNRX: רווח עתידי חזוי VolitionRx Ltd 02.04.2025 - 23.05.2026

פילוחים אנליטיים ודוחות נתונים של חברת VolitionRx Ltd (VNRX)

- מחיר ותחזית קונצנזוס למחירים:
ניתוח מסכם של החברה:VolitionRx Limited
מוצרים מוגמרים של VolitionRx Ltd.

Strategic partnerships within the US veterinary sector to implement Nu.Q diagnostics provide stability for VolitionRx Limited (VNRX). By analyzing the company's estimated earnings on GURU.Markets, an investor can view the market participants' consensus forecast. This metric measures the expected financial result, filtering out short-term volatility through a daily data series. This enables the calculation of Sharpe and Sortino ratios. This corridor determines the fair value of the business, eliminating the risk of purchasing the asset at a local peak.